H.C. Wainwright analyst Patrick Trucchio has reiterated their bullish stance on DTIL stock, giving a Buy rating on August 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Patrick Trucchio has given his Buy rating due to a combination of factors including the promising clinical and regulatory milestones that Precision BioSciences is poised to achieve. The company is advancing its ARCUS platform with key programs such as PBGENE-HBV and PBGENE-DMD, which are expected to hit significant clinical milestones in the near future. Notably, the Phase 1 ELIMINATE-B trial for PBGENE-HBV has already demonstrated favorable safety and activity at low doses, with further dose escalation expected to enhance antiviral durability.
Additionally, Precision BioSciences is preparing for an investigational new drug application for PBGENE-DMD, targeting a substantial portion of Duchenne muscular dystrophy patients. The company’s collaborations are also progressing, with important data and regulatory meetings anticipated in the coming years. With a strong cash position extending into the second half of 2027 and a clear path to value inflection points, Trucchio sees a substantial upside potential for the stock over the next year.
In another report released on August 6, JonesTrading also maintained a Buy rating on the stock with a $30.00 price target.
Based on the recent corporate insider activity of 23 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of DTIL in relation to earlier this year.